2017 American Transplant Congress
Rituximab Desensitization (DES) and Alemtuzumab Induction Significantly Reduced EBV Viremia and Post-Transplant Lymphoproliferative Disorder (PTLD) in HLA-Sensitized (HS) Kidney Transplant Patients.
Background: PTLD is a serious complication in KTx pts and is usually associated with EBV infection. Recent studies showed that rituximab treatment prior to Tx…2017 American Transplant Congress
Tacrolimus and Mycophenolic Acid Have a Limited Inhibitory Effect on Monocyte Signaling Pathway Phosphorylation, Function and Differentiation.
Introduction Monocytes and macrophages play key roles in cellular and humoral rejection after solid organ transplantation, but little is known about the effects of the…2017 American Transplant Congress
The Inhibitory Effect of Plasma on T Cell Activation: Possible Role of Plasma Exchange in Anti Rejection Therapy.
Reduction of lymphocyte proliferation by human plasma has been previously reported. Reduced activation of lymphocytes of patients on immunosuppressive drugs is well documented.Aim: To compare…2017 American Transplant Congress
Clinical Outcomes of Kidney Transplant Recipients by Steroid Early Withdraw Protocol with Basiliximab Induction.
Urology, Hokkaido University Hospital, Sapporo, Japan
[Purpose] Several steroid early withdrawal protocols (SEWD) have been attempted in recent decades to avoid steroid related adverse effects among kidney transplant recipients. However, there…2017 American Transplant Congress
Time to First Therapeutic Tacrolimus Level: What Impact Does It Have After Heart Transplantation?
University of Pittsburgh Medical Center, Pittsburgh, PA
Purpose: Appropriate time to therapeutic immunosuppression levels is not well defined. The purpose of this study is to investigate outcomes related to time to therapeutic…2017 American Transplant Congress
Generation of Potent Monocytic Myeloid-Derived Suppressor Cells from Rhesus Macaque Bone Marrow.
Surgery (Transplant), University of Pittsburgh, Pittsburgh, PA
Background: Myeloid-derived suppressor cells (MDSC) have shown promise in inhibiting allograft rejection and in promoting transplant tolerance in rodent models. We recently reported that monocytic…2017 American Transplant Congress
One Year Outcomes of Low-Dose vs Very Low-Dose Extended-Release Tacrolimus/Mycophenolate mofetil in De Novo Kidney Transplantation: A Multi-Center Randomized Controlled Trial.
Purpose: Once-daily tacrolimus extended-release formulation (TACER) has now been widely accepted in kidney transplant field. However, the optimal dosage for TACER is still not known.Patients…2017 American Transplant Congress
Risks Associated with Recombinant IL2 Therapy in Renal Transplantation.
Brigham and Women's Hospital, Boston
Regulatory T cells are critical to allograft survival. We report a pilot study of safety and tolerability of low dose recombinant IL2 (rIL2), 1x106 units/m2/day…2017 American Transplant Congress
National Variation in Liver Transplant Immunosuppression in the U.S..
Variation in immunosuppression (ISx) for liver transplant (LTx) across US programs has not been described. We examined a novel database integrating national registry and pharmacy…2017 American Transplant Congress
Risk Factors for Post-Transplant Lymphoproliferative Disorders in Epstein-Barr Virus Mismatch Lung Transplant Recipients.
Brigham and Women's Hospital, Boston
Background: Post-transplant lymphoproliferative disorders (PTLD) are associated with significant morbidity and morality. Lung transplant patients appear to have higher rates of PTLD than other solid…
- « Previous Page
- 1
- …
- 90
- 91
- 92
- 93
- 94
- …
- 138
- Next Page »